Filing Analysis
Material Agreement
Filed Mar 25, 2026
HIGH
Synergy CHC Corp. entered into a second amendment to its credit agreement with ACP Agency, LLC, restructuring its debt obligations due to apparent liquidity constraints. The amendment includes provisions for paid-in-kind (PIK) interest, a mandatory $10 million equity raise requirement, and the issuance of 3 million nominal-price warrants to the lender that become exercisable upon a default.
Red Flags
- Paid-in-kind (PIK) interest indicates the company is unable to meet cash interest obligations.
- Extremely high leverage covenant (20.00:1.00) suggests severe financial distress.
- Issuance of 'penny' warrants to a lender that trigger on default is highly dilutive and indicative of distressed debt restructuring.
- Mandatory equity raise requirement of $10M is significant relative to typical micro-cap liquidity.
- Automatic conversion of SOFR loans to Reference Rate loans typically increases the cost of capital.
Key Facts
- The amendment restructures the amortization schedule with principal payments starting at $175,000 in July 2026 and increasing to $350,000 quarterly by April 2027.
- Interest due on March 2, 2026, was paid-in-kind (capitalized into principal), and the April 1, 2026, payment may also be PIK.
- The company must raise at least $10,000,000 in net cash proceeds from equity issuances by September 30, 2026, or face a 2.00% per annum interest rate increase.
- Financial covenants were revised to include a maximum senior net leverage ratio of 20.00:1.00 for the quarter ended December 31, 2025.
- A warrant for 3,000,000 shares was issued to the lender at an exercise price of $0.00001, exercisable upon a 'Qualified Event of Default'.
- Effective February 1, 2026, all Term SOFR loans were converted to higher-cost Reference Rate Loans until $4,000,000 in principal is repaid.
Other SEC Filing
Filed Mar 03, 2026
HIGH
Synergy CHC Corp. received notice that Gravity Pharma General Trading LLC is terminating a $2.9 million brand license agreement 'ab initio.' The agreement, which covered the UAE and Turkey markets, had its license fee previously recognized as revenue by the company.
Red Flags
- Termination 'ab initio' strongly implies that the $2.9 million in previously recognized revenue may need to be reversed or restated.
- Loss of a significant international licensing partner for core brands.
- Potential for legal disputes or financial instability following the loss of the $2.9 million fee.
Key Facts
- Termination notice received on February 27, 2026, from Gravity Pharma General Trading LLC.
- The Brand License Agreement was originally dated March 31, 2025, and amended June 30, 2025.
- The agreement involved an aggregate license fee of $2.9 million for FOCUSfactor and Flat Tummy Co. products.
- The territory covered was the United Arab Emirates and Turkey.
- The company had already accounted for the $2.9 million fee as revenue.
- Termination is specified as 'ab initio' (from the beginning).
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.